FDA grants accelerated approval to AstraZeneca's Etcamah for ESR1-mutant breast cancer despite an adcomm rejection; Jefferies sees $5B+ peak sales.
AstraZeneca clinched an FDA accelerated approval for its oral SERD in certain breast cancer patients Friday, even after a negative vote from …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Oral SERD camizestrant lands indication for use in novel first-line treatment strategy
Europe's CHMP backed AstraZeneca's camizestrant for breast cancer, diverging from a recent FDA committee vote, as well as Novo…
The FDA has delayed a decision on the approval of AstraZene | The FDA has delayed a decision on the approval of AstraZeneca’s…
AbbVie’s ultra-rare blood cancer ADC secured FDA clearance while AstraZeneca’s oral SERD for breast cancer remains in regulatory…
Less than a month after an FDA advisory committee voted 6-3 | Less than a month after an FDA advisory committee recommended…
The advisory panel wasn't convinced that a clinical trial proved that early switching to camizestrant improved long-term survival…
